Absci (ABSI) and Owkin said Friday that they formed a partnership to develop therapeutic candidates addressing novel targets in immuno-oncology and other indications such as inflammation.

The partnership will use Owkin's predictive AI models to optimize target selection and validate therapeutic hypotheses, while Absci's generative AI Drug Creation platform will design therapeutic candidates against the selected novel targets, according to a joint statement.

Financial terms were not disclosed.

Shares of Absci were down more than 9% in recent trading.

Price: 2.92, Change: -0.30, Percent Change: -9.32